Friday , November 17 2017
Home / Specialty Pharmacy

Specialty Pharmacy

CMS Proposes Policies to Lower the Cost of Prescription Drugs and Combat the Opioid Crisis

Today, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that includes a number of changes that, if finalized, will ensure that Part D Medicare enrollees have access to more affordable prescription drugs and more robust prescription drug coverage at the pharmacy they prefer. The rule also …

Read More »

Alnylam Starts Rolling FDA Filing for Patisiran for the Treatment of Hereditary ATTR

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR), for the treatment of hereditary ATTR (hATTR) amyloidosis. …

Read More »

Diplomat to Acquire LDI Integrated Pharmacy Services

FLINT, Mich., Nov. 15, 2017 /PRNewswire/ — Diplomat Pharmacy, Inc. (NYSE: DPLO), has entered into a definitive agreement to acquire Leehar Distributors, LLC, doing business as LDI Integrated Pharmacy Services (LDI), from investment firms Nautic Partners, LLC and Oak HC/FT Partners LLC, and management. The transaction is expected to close …

Read More »

Acorda Halts Enrollment in Late-Stage Parkinson’s Disease Trial Following Five Patient Deaths

ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc.(Nasdaq:ACOR) today announced that it has increased the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson’s disease. The Company took this action in response to cases of agranulocytosis, possibly drug-related, and in some cases associated …

Read More »

Allergan’s Vraylar Receives FDA Approval for Use in the Maintenance Treatment of Schizophrenia

DUBLIN, Nov. 13, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for VRAYLAR™ (cariprazine) for the maintenance treatment of adults with schizophrenia. VRAYLAR is also approved in the U.S. in adults for the acute treatment of schizophrenia and acute treatment …

Read More »

McKesson to Acquire CVS Health’s Specialty Distribution Unit RxCrossroads for $735 Million

SAN FRANCISCO–(BUSINESS WIRE)–McKesson Corporation (NYSE:MCK) today announced that it has signed a definitive agreement to purchase RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health Corporation (NYSE:CVS). The transaction is valued at $735 million, or approximately $635 million net of the present value of incremental …

Read More »

Amgen and Novartis Expand Collaboration with Banner Alzheimer’s Institute in Pioneering Prevention Program

THOUSAND OAKS, Calif., Nov. 2, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Novartis today announced an expanded collaboration with the Banner Alzheimer’s Institute (BAI) to initiate a new trial – the Alzheimer’s Prevention Initiative (API) Generation Study 2. This trial follows the launch of the Generation Study 1, and will …

Read More »

Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Aducanumab in Alzheimer’s Disease

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) will present new data from the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment for Alzheimer’s disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting, Boston, November 1 – 4. The data include results from patients in the …

Read More »

Boehringer Ingelheim and Dicerna Partner to Develop Novel Treatments for Chronic Liver Diseases

INGELHEIM, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced a research collaboration and license agreement to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases. The partnership will initially focus on …

Read More »

bluebird bio to Present New Data from Studies of its Therapies for Sickle Cell Disease and Multiple Myeloma

CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that four oral and seven poster presentations will feature data from bluebird programs during the 59th Annual Meeting of the American Society …

Read More »